Benjamin Martinez-Andujo, NP
Family · Keenesburg, CONPI 1952321150
Payments from drug & device makers
Across 109 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$399
- Bayer$384
- Lilly USA, LLC$291
- AbbVie$233
- Teva Pharmaceuticals USA, Inc.$189
- Novo Nordisk$73
- plus $399 from 13 others
What the payments were for
- Food & beverage$1,968100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 22 | $399 |
| Bayer | 23 | $384 |
| Lilly USA, LLC | 19 | $291 |
| AbbVie | 12 | $233 |
| Teva Pharmaceuticals USA, Inc. | 9 | $189 |
| Novo Nordisk | 4 | $73 |
| Exact Sciences | 4 | $73 |
| Merck | 3 | $49 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $45 |
| Nestle Healthcare Nutrition Inc. | 2 | $37 |
| Mylan Specialty L.p. | 1 | $31 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $29 |
| Organogenesis Inc. | 1 | $25 |
| Boehringer Ingelheim | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Baxter Healthcare | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $14 |
| Abbott | 1 | $13 |
How this compares
$1,968 in reported general payments places this provider in the 85th percentile of 2,182 family providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 94 | $67,831 |
| EliquisApixaban | 92 | $66,198 |
| JanuviaSitagliptin Phosphate | 57 | $43,931 |
| MounjaroTirzepatide | 38 | $43,256 |
| MyrbetriqMirabegron | 41 | $31,521 |
| OxycontinOxycodone Hcl | 23 | $29,165 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $19,292 |
| XareltoRivaroxaban | 24 | $16,563 |
| TrulicityDulaglutide | 16 | $15,402 |
| Spiriva HandihalerTiotropium Bromide | 23 | $13,780 |
| TradjentaLinagliptin | 23 | $11,988 |
| JardianceEmpagliflozin | 12 | $10,413 |
| Spiriva RespimatTiotropium Bromide | 15 | $10,222 |
| TrulancePlecanatide | 13 | $7,532 |
| KerendiaFinerenone | 12 | $7,528 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $399 | $93,468143 claims |
| Lilly USA, LLCMounjaro, Trulicity | $291 | $58,65754 claims |
| MerckJanuvia | $49 | $43,93157 claims |
| Boehringer IngelheimTradjenta, Jardiance, Spiriva Respimat, Pradaxa | $22 | $34,97461 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $31,52141 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $45 | $7,53213 claims |
| BayerKerendia | $384 | $7,52812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,182 family providers in Colorado.
Other family in Keenesburg
- Laura GrahamLakewood$1.6M
- Corinne YoungColorado Springs$272K
- Margaret MachaffieColorado Springs$97K
- April RossGrand Junction$95K
- Jeannette LillerColorado Springs$74K
- Teal MeffordThornton$63K
- Jacquita JordanColorado Springs$52K
- Stephanie HanenbergColorado Springs$40K
- Courtney WeirFort Collins$30K
- Katie NadingDenver$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.